BioSpace News Archive

Catalyst Pharmaceuticals, Inc. today announced that it will release its third-quarter 2023 financial results after market close on Wednesday, November 8, 2023.

Protara Therapeutics, Inc. today announced that dosing is now underway in the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs).

Elucida Oncology announced today that new data have been presented from its recently completed dose escalation/safety phase of its first-in-human Phase 1/2 clinical trial evaluating ELU001, its lead C’Dot drug conjugate (CDC) clinical candidate, at the ESMO Congress 2023 being held in Madrid, Spain.

Sensei Biotherapeutics, Inc. today presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

INVO Bioscience, Inc. and NAYA Biosciences Inc. today jointly announced that they have entered into a definitive merger agreement (the “Merger”) for INVO to acquire NAYA Biosciences in an all-stock transaction.

Palatin Technologies, Inc. today announced that it has entered into a definitive agreement with an institutional investor for the issuance and sale of an aggregate of 2,358,491 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.12 per share of common stock (or common stock equivalents in lieu thereof).

Sumitomo Pharma Canada, Inc., announced today that Health Canada has approved ORGOVYX ® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist.

SEED Therapeutics has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors.

Theralase Technologies Inc. announced that it has been granted a Clinical Trial Application Amendment (“CTA-A”) by Health Canada through receipt of a No Objection Letter (“NOL”) for the optimization of the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”).

Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress.